• Text in Japanese

Immunotherapy technologies for controlling the immune system with high quality control

We have developed a method that modifies glycosylation levels for the quality control of immune cells towards future cancer immunotherapies. Specifically, we are modifying the glycosylation of activated T cells. When introducing a chimeric antigen receptor (CAR) to patient T cells, both the quality of the CAR and the T cell activity are essential. Therefore, we are developing screening methods for high CAR quality. Using this screening technology with glycosylation-modified T cells, we aim to develop an immunotherapy applicable to cancer treatment.